Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of Canadian Patent No. 2,893,962 for its immunotherapy product candidate AllocetraTM, providing additional protection for its pharmaceutical compositions and manufacturing methods. The patent enhances Enlivex's intellectual property portfolio, contributing to its focus on treating life-threatening diseases such as sepsis, COVID-19, and solid tumors. CEO Oren Hershkovitz emphasized the importance of this patent in supporting their clinical development efforts aimed at addressing significant unmet medical needs.
- Issuance of Canadian Patent No. 2,893,962 for AllocetraTM enhances intellectual property protection.
- Strengthens Enlivex's position in the immunotherapy market targeting high mortality diseases.
- None.
Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 2,893,962 covering AllocetraTM, the Company’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection for pharmaceutical compositions, manufacturing methods and uses of AllocetraTM.
Oren Hershkovitz, PhD, CEO of Enlivex, stated, “We are pleased to have this patent granted in Canada, which adds to existing AllocetraTM patents in various countries around the world. We currently continue to focus our clinical development efforts on life-threatening diseases with high mortality rates and no effective treatments such as sepsis, COVID-19, and solid tumors.”
AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
FAQ
What does the new Canadian Patent for AllocetraTM by Enlivex mean?
How does the patent affect Enlivex's market position?
What diseases is AllocetraTM targeting?
What is the significance of the patent for Enlivex's clinical development?
When was the patent for AllocetraTM issued?
